Clinical Trial on Efficacy of rTMS to Improve ECT in Treatment-Resistant Depression
Launched by CENTRE HOSPITALIER DU ROUVRAY · Jul 8, 2016
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
Included patients are adults, aged between 18 and 70 years, with major depression (Hamilton Rating scale for Depression, HAMD ≥ 15). Patients don't have any experience concerning repeated Transcranial Magnetic Stimulation (rTMS).
Patients with treatment-resistant depression (TRD) were assigned to two treatment groups in addition to their current pharmacotherapy regimen : one group received 5 active-rTMS before Electroconvulsive therapy (ECT) and the other one received sham-rTMS before ECT. The depressive symptoms and the cognitive functions are evaluated before rTMS, after 5 rTMS and after...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with Major Depressive Disorder (HAMD≥15)
- • Level of resistance ≥ 3 (Thase and Rush)
- • Participants who gave their informed, written consent
- Exclusion Criteria:
- • Contraindication of Electroconvulsive therapy (ECT), repeated Transcranial Magnetic Stimulation (rTMS), Magnetic Resonance Imaging (MRI), anesthesia
- • History of epilepsy; severe neurological or systemic disorder that could significantly affect cognition
- • Pregnancy
About Centre Hospitalier Du Rouvray
The Centre Hospitalier du Rouvray is a leading psychiatric hospital located in France, dedicated to advancing mental health care through innovative research and clinical trials. With a commitment to enhancing patient outcomes, the institution focuses on a multidisciplinary approach, integrating clinical expertise with cutting-edge methodologies. The Centre Hospitalier du Rouvray collaborates with various stakeholders, including academic institutions and healthcare organizations, to develop and evaluate novel treatment interventions and therapeutic strategies. Its research initiatives aim to address critical challenges in mental health, contributing to the global body of knowledge and fostering improvements in psychiatric care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Caen, , France
Poitiers, , France
Sotteville Lès Rouen, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials